mCRPC VL

NCCN Guidelines Updated for Prostate Cancer M1 Systemic Therapy Based Upon The CARD Trial - Tanya Dorff

Details
Tanya Dorff joins Alicia Morgans discussing recent updates to the NCCN guidelines for systemic therapies in the treatment of M1 prostate cancer. The CARD trial was a multicenter, randomized, open-label study that enrolled men with metastatic castration-resistant prostate cancer (mCRPC) between 2015 and 2018. Patients were eligible if they had evidence of symptomatic progressive disease within 12 m...

The Progress and Promise of Prostate Cancer Treatments in 2020 - Charles Ryan & Alicia Morgans

Details
Treatments in advanced prostate cancer continued to progress from research into clinical practice throughout 2020. Alicia Morgans, MD, MPH, and Charles Ryan, MD, discuss trials that matured, new drugs that were approved, and novel molecular imaging that transformed the prostate cancer treatment continuum. Biographies: Charles J. Ryan, MD , The B.J. Kennedy Chair in Clinical Medical Oncology at the...

Improving Quality Imaging in Prostate Cancer with Gallium 68 PSMA-11 - Johannes Czernin

Details
68 Ga-PSMA-11, the first drug for PET imaging of prostate-specific membrane antigen (PSMA)–positive lesions in men with prostate cancer (PC), was approved on December 1, 2020, by the United States Federal Drug Administration (FDA). Joining Phillip Koo is Johannes Czernin, one of the original pioneers who started the process of getting gallium-68 PSMA approved in the United States. Dr. Czernin deta...

Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Castration-Resistant Prostate Cancer - Karim Fizazi

Details
In the CARD study, cabazitaxel significantly improved radiographic progression-free survival and overall survival versus abiraterone or enzalutamide in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel and the alternative androgen signaling-targeted inhibitor. Here, we report the quality-of-life outcomes from the CARD study. In the quality-of-life anal...

Treatment Considerations For Disease Progression After Combination Therapy in mCRPC - Alicia Morgans

Details
Alicia Morgans, MD, MPH presents a State of Art Lecture on treatment selection for mCRPC patients who have disease progression progressing after combination treatment for in metastatic castration-sensitive prostate cancer (mCSPC). The learning objectives of this presentation include to understand the rationale for avoiding sequencing of androgen receptor-targeted agents one after another, how to c...

PROfound: Olaparib for Metastatic Castrate Resistant Prostate Cancer - Thomas Keane

Details
Thomas Keane highlights the PROfound Study, Olaparib for Metastatic Castrate Resistant Prostate Cancer , published in the New England Journal of Medicine this year. The study found that in men with metastatic prostate cancer with genetic alterations relating to homologous recombination repair who have shown disease progression while receiving ezalutamide or abiraterone, olaparib was associated wit...

Effect of Cabazitaxel vs Abiraterone or Enzalutamide on Patient-Reported Outcomes in mCRPC: A Pre-Planned EQ-5D-5L Analysis of the CARD Study - Neal Shore

Details
Neal Shore, MD, FACS joins Alicia Morgans, MD, MPH to discuss the outcomes of the CARD trial, Cabazitaxel Versus the Switch to Alternative AR-targeted Agent (Enzalutamide or Abiraterone) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients Previously Treated With Docetaxel and Who Rapidly Failed a Prior AR-targeted Agent (CARD) in a recent analysis presented at the AUA 2020 Virtual...

Cabazitaxel Demonstrates Improved Overall Survival when Compared to an Alternative AR-targeted Agent (CARD) - Cora Sternberg

Details
Cora Sternberg, MD, FACP, shares her experiences from the CARD study, which was the first trial to evaluate the sequencing of the androgen-signaling–targeted inhibitor (abiraterone or enzalutamide) compared to cabazitaxel in patients with metastatic castration-resistant prostate cancer (mCRPC) who had been previously treated with docetaxel and the alternative androgen-signaling–targeted agent (abi...

The Clinical Implications of The Efficacy and Safety in Older Patients with Metastatic Castration-Resistant Prostate Cancer Receiving Cabazitaxel versus Abiraterone or Enzalutamide In The CARD Trial -...

Details
William Oh and Stephen Freedland join Alicia Morgans to discuss the efficacy and safety in older patients with metastatic castration-resistant prostate cancer (mCRPC) receiving cabazitaxel versus abiraterone or enzalutamide an analysis of the CARD Trial. Prostate cancer is the 2nd and 3rd leading cause of cancer death in the USA and in Europe, respectively, with most deaths occurring in men over t...

Rucaparib, A PARP Inhibitor For The Treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC) - Wassim Abida

Details
Lead author of the TRITON-2 study, Wassim Abida joins Charles Ryan to talk about the recent approval of rucaparib, the first PARP Inhibitor approved for men with metastatic castration-resistant prostate cancer (mCRPC) and a deleterious BRCA mutation. This approval was based on findings from the TRITON-2 study, rucaparib for post-chemotherapy mCRPC patients who have previously received one AR-targe...